Skip to main content
News Krawitz 11.2021
© UKB

News categories: Publication

Artificial Intelligence helps diagnose Leukemia

Software trained with more than 30.000 data sets from B-Cell Lymphoma patients


ImmunoSensation2 Member Prof. Dr. Peter Krawitz and his team showed, how artificial Intelligence can help in the diagnosis of lymphomas and leukemias already in 2020. The machine learning method developed by the scientists has since been further developed. It is made freely accessible and may be utilized also by smaller laboratories. The respective study has now been published in "Patterns".

Leukemia diagnostics relies on the analysis of blood- or bone marrow samples by flow cytometry. Large amounts of data are generated, as various markers are needed in addition to parameters like cell-size and -shape. “With 20 markers, the physician would already have to compare about 150 two-dimensional images," says Prof. Dr. Peter Krawitz from the Institute for Genomic Statistics and Bioinformatics at Bonn University Hospital. "That's why it's usually too costly to sift through the entire data set thoroughly."

In order to train the artificial intelligence (AI), Prof. Krawitz and the bioinformaticians Nanditha Mallesh and Max Zhao analyzed more than 30,000 data sets from patients with B-cell lymphomas. "The AI takes full advantage of the data and increases the speed and objectivity of the diagnoses," says Nanditha Mallesh. Still, the result presented by the AI can only be considered as suggestion and has to be reviewed by the physician. "The point of using AI is not to replace physicians, but to make the best use of the information contained in the data in the best possible way." Prof. Krawitz states.

The big step that brings the method closer to a broad clinical application is the free availability of the AI. The knowledge transfer offered also enables small laboratories to benefit from the development. Only a short training period is needed for the AI to internalize the specifics of the new lab. Subsequently, the knowledge derived from many thousands of data sets is available. All raw data and the complete software are open source and thus freely accessible. "With https://hema.to, we want to enable the exchange of anonymized flow cytometry data between laboratories and thus create the conditions for even higher quality in diagnostics," says Dr. Hannes Lüling from res mechanica.

The team sees great potential in this technology. For the diagnosis of B-cell lymphomas, also genetic and cytomorphological data are collected. "If we can succeed in using AI for these methods as well, then we would have an even more powerful tool," says Prof. Krawitz.


Funding

The study was funded by the German Research Foundation.


Publication

Nanditha Mallesh, Max Zhao, Lisa Meintker, Alexander Höllein, Franz Elsner, Hannes Lüling, Torsten Haferlach, Wolfgang Kern, Jörg Westermann, Peter Brossart, Stefan W. Krause, Peter M. Krawitz: Knowledge transfer to enhance the performance of deep learning models for automated classification of B-cell neoplasms, Patterns, DOI: 10.1016/j.patter.2021.100351

Contact

Prof. Dr. med. Dipl. Phys. Peter Krawitz

Institute for Genomic Statistics and Bioinformatics

University Hospital Bonn

Phone +49 228 287 14799

E-mail: pkrawitz@uni-bonn.de

Related news

News Icon

News categories: Publication

Twin Lancet Publications Highlight Promising New Approach for Lupus Treatment

A team of international researchers, including ImmunoSensation³ member Prof. Jörg Wenzel, reports promising phase 2 results for enpatoran, a first-in-class oral TLR7/8 inhibitor, in patients with cutaneous and systemic lupus erythematosus (CLE/SLE). In the WILLOW trial, enpatoran significantly improved skin disease activity in a dose-dependent manner and showed favourable safety outcomes. In systemic SLE, treatment also reduced global disease activity and rapidly suppressed the type I interferon gene signature. The twin studies were published in The Lancet and The Lancet Rheumatology.
View entry
Wissenschaftler

News categories: Publication

Driver of inflammation after mild head injury

Mild traumatic brain injuries can lead to persistent memory problems and an increased risk of dementia. Yet, effective therapies to counteract these long-term consequences are still lacking. Dr. Dr. Sergio Castro-Gomez, Early Career Research Group Leader at the Institute of Physiology II of the University Hospital Bonn has discovered together with colleagues that the ASC protein. The research team hopes to identify new targets for future therapeutic strategies. The study, published in the Journal of Clinical Investigation, lays the foundation for upcoming clinical trials.
View entry
PM Immunity Nebeling

News categories: Publication

Study reveals dynamic interactions between brain tumors and immune cells

Glioblastoma, the most common and aggressive brain tumor in adults, is difficult to treat because this cancer can invade the surrounding brain tissue and spread far beyond the original tumor mass. Researchers from the DZNE, the University Hospital Bonn (UKB), and ImmunoSensation³ at the University of Bonn have observed this infiltration process in the living brain using high-tech microscopy. Their study is based on research in mice with a form of brain tumor that closely resembles human glioblastoma.
View entry

Back to the news overview